Literature DB >> 7795225

Enzyme-linked immunoabsorbent assay detection of a soluble form of urokinase plasminogen activator receptor in vivo.

I F Mizukami1, N E Faulkner, M R Gyetko, R G Sitrin, R F Todd.   

Abstract

The receptor for urokinase plasminogen activator (uPA-R, CD87) is a glycosylphosphatidylinositol (GPI)-anchored 50 to 65 kD glycoprotein that, by regulating membrane-associated plasmin activity, may facilitate the invasion of inflammatory and malignant cells. Certain other GPI-anchored glycoproteins are shed from the cell membrane and exist as soluble products in vitro and in vivo. To determine if uPA-R undergoes a similar phenomenon, we have developed a sensitive enzyme-linked immunoabsorbent assay (ELISA) (using a rabbit antiserum as both capture and detection reagents) to measure the quantity of soluble uPA-R (suPA-R) in tissue culture supernatants and biologic fluids. Using this ELISA, we have detected suPA-R in the culture supernatants of U-937 cells and human monocytes stimulated in vitro by certain soluble inflammatory mediators (Sitrin et al, Blood 84:1268, 1994; Mizukami et al., Clin Res 42:115A, 1994). To determine if suPA-R exists in vivo, we have screened the plasma of 20 normal volunteers (mean +/- SD, 3 +/- 3 ng/mL; median, 2 ng/mL; range, 1 to 11 ng/mL [serum values slightly higher]); the plasma of 13 ICU patients with clinical sepsis syndrome (mean +/- SD, 30 +/- 11 ng/mL; median, 11 ng/mL; range, 4 to 221 ng/mL); and the extravascular fluids (pleural, pericardial, and peritoneal) of 84 individuals with presumed inflammatory or malignant conditions (mean +/- SD, 21 +/- 39 ng/mL; median, 10 ng/mL; range, 2 to 253 ng/mL). Among the latter specimens, most were inflammatory exudates (only six were malignant by positive cytology) with the highest quantities of suPA-R associated with neutrophilic exudates. The solubility of suPA-R contained within these fluids was confirmed by reanalysis after ultracentrifugation to remove particulate material. When tested in a uPA ligand capture ELISA, representative specimens of extravascular body fluids and sepsis plasma contained suPA-R capable of binding uPA ligand (generally representing a small fraction of the immunoreactive material). We conclude from these data that suPA-R is immunologically detectable in vitro and in vivo with high concentrations of receptor found under conditions of inflammatory stimulation. The possibility of suPA-R's biologic activity is suggested by its partial retention of ligand binding capacity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7795225

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

Review 1.  Developments for improved diagnosis of bacterial bloodstream infections.

Authors:  A J M Loonen; P F G Wolffs; C A Bruggeman; A J C van den Brule
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-22       Impact factor: 3.267

2.  Differential expression of the urokinase receptor (CD87) in arthritic and normal synovial tissues.

Authors:  Z Szekanecz; G K Haines; A E Koch
Journal:  J Clin Pathol       Date:  1997-04       Impact factor: 3.411

3.  Detection of a soluble form of the leukocyte surface antigen CD48 in plasma and its elevation in patients with lymphoid leukemias and arthritis.

Authors:  G M Smith; J Biggs; B Norris; P Anderson-Stewart; R Ward
Journal:  J Clin Immunol       Date:  1997-11       Impact factor: 8.317

4.  Upregulation of monocyte urokinase plasminogen activator receptor during human endotoxemia.

Authors:  P E Dekkers; T ten Hove; A A te Velde; S J van Deventer; T van Der Poll
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

5.  GPI-specific phospholipase D mRNA expression in tumor cells of different malignancy.

Authors:  H Xiaotong; Melanie-Jane Hannocks; Ian Hampson; Georg Brunner
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

6.  Release of the soluble urokinase-type plasminogen activator receptor (suPAR) by activated neutrophils in rheumatoid arthritis.

Authors:  Boris K Pliyev; Mikhail Yu Menshikov
Journal:  Inflammation       Date:  2010-02       Impact factor: 4.092

Review 7.  Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review.

Authors:  Yara Backes; Koenraad F van der Sluijs; David P Mackie; Frank Tacke; Alexander Koch; Jyrki J Tenhunen; Marcus J Schultz
Journal:  Intensive Care Med       Date:  2012-06-16       Impact factor: 17.440

8.  Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group.

Authors:  Claudio Sorio; Andrea Mafficini; Federico Furlan; Stefano Barbi; Antonio Bonora; Giorgio Brocco; Francesco Blasi; Giorgio Talamini; Claudio Bassi; Aldo Scarpa
Journal:  BMC Cancer       Date:  2011-10-14       Impact factor: 4.430

Review 9.  suPAR as a prognostic biomarker in sepsis.

Authors:  Katia Donadello; Sabino Scolletta; Cecilia Covajes; Jean-Louis Vincent
Journal:  BMC Med       Date:  2012-01-05       Impact factor: 8.775

10.  Soluble urokinase-type plasminogen activator receptor levels in patients with burn injuries and inhalation trauma requiring mechanical ventilation: an observational cohort study.

Authors:  Yara Backes; Koenraad F van der Sluijs; Anita M Tuip de Boer; Jorrit Jan Hofstra; Alexander P J Vlaar; Rogier M Determann; Paul Knape; David P Mackie; Marcus J Schultz
Journal:  Crit Care       Date:  2011-11-16       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.